Intuitive Surgical (ISRG)
Health Care · medical robotics and surgical equipment · NASDAQ
Intuitive Surgical is the dominant innovator and market leader in robotic-assisted surgical platforms, driving a shift toward minimally invasive clinical outcomes.
What Intuitive Surgical does
Intuitive Surgical designs, manufactures, and markets robotic-assisted surgical systems for minimally invasive surgery. The company generates revenue from both product sales (surgical systems hardware) and recurring service revenue from maintenance, support, and training. The da Vinci surgical platform is the company's flagship product, used in hospitals and surgical centers worldwide for a wide range of surgical procedures.
Themes: robotic surgery, minimally invasive surgery, surgical robotics, medical devices
Fundamentals
- Price$373.57 as of 2026-08-24 close
- Market cap$132.0B as of 2026-08-24
- 1-year return-21.5% 2025-08-22 close $476.16 → 2026-08-24 close $373.57
- P/E42.81 as of 2026-08-24
- Net margin+28.4% as of 2026-08-24
- Gross margin+66.7% as of 2026-08-24
- ROE+17.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+20.7% as of 2026-08-24
- Revenue CAGR (3y)+17.4% SEC XBRL
- Beta1.16 as of 2026-08-24
- Last reported earnings2026-07-16 SEC EDGAR Form 8-K (Item 2.02)
How ISRG compares in its sector
- price-to-earnings ratiomiddle range 191 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ISRG is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
36.5 #1518 of 1,704 scored · #219 of 240 in Health Care
Catalysts 64th: the analyst consensus rating has improved toward "buy" since the prior reading; momentum 49th: MACD momentum is positive; weakest is setup 10th: no fresh 20-day breakout up or down.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Intuitive Surgical looks technically
Intuitive Surgical (ISRG) is trading 20.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 105 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 22 trading days ago. It is 37.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 20.2% below its 200-day average, the long-term trend line — a long-term downtrend | -20.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $388.34 | $388.34 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $474.91 | $474.91 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 105 trading days ago — a "death cross", a bearish long-term signal | 105 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 47.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($364.26 to $405.22) — its "stochastic" reading is 36 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 35.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $603.88 | $603.88 |
|---|---|---|
| From the 52-week high | it is 37.3% below its 52-week high (its highest price of the past year) | -37.3% |
| Above the 52-week low | it is 15.3% above its 52-week low (its lowest price of the past year) | +15.3% |
| Below the 52-week high | it is 37.3% below its highest point of the past year | 37.3% |
| Since a 20-day breakout | it made a new 20-day low about 22 trading days ago | 22 sessions |
| Since a 55-day breakout | it made a new 55-day low about 22 trading days ago | 22 sessions |
| All-time high | its highest closing price on record is $616.00 (set on 2025-01-23) | $616.00 |
| Given back of the 52-week move | over the past year its closes ranged ($332.02 to $592.85), and it has recovered roughly a quarter of its fall from last year’s high — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $493.21 to $501.56. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.9% |
| From the all-time high | it is 38.5% below its all-time high | -38.5% |
| Nearest price level | it is trading 4.8% below a resistance level at $397.10 — a price it turned at twice since 2026-06-02, most recently on 2026-06-30. Since 2024-08-21 it has 0 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.8% |
| All-time low | its lowest closing price on record is $0.6667 (set on 2001-04-03) | $0.6667 |
| Above the all-time low | it is 56721.5% above its all-time low | +56,722% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $13.05 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $13.05 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $345.38 and $411.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $345.38 – $378.68 – $411.98 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 7.4 daily ranges below its 200-day average price (20.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.54× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.2% since the prior reading | +0.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.06 toward buy |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 14 sessions ago and has not traded back through the level it left behind at 353.33 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.4% gap up opened on 2026-07-28 has been "filled" 17 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 17 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.9 percentage points (the stock gained 8.2% while the market gained 2.3%) | +5.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 17.0 percentage points (the stock lost 13.9% while the market gained 3.1%) | -17.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 35.9 percentage points (the stock lost 24.8% while the market gained 11.1%) | -35.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 39.9 percentage points (the stock lost 19.4% while the market gained 20.5%) | -39.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.9% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.0% of the share price. | -7.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $437.20 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -13.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-07-16 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $367.08 — a volume-weighted average of daily closes over 27 sessions, not a true tick-by-tick VWAP. | +3.2% |
Price levels it has turned at before
ISRG last closed at $378.81 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 12 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $397.10 | Resistance | 4.8% above the last close | turned there twice · 2026-06-02 to 2026-06-30 |
| $428.28 | Resistance | 13.1% above the last close | turned there five times · 2025-04-07 to 2026-06-05 |
| $448.81 | Resistance | 18.5% above the last close | turned there five times · 2025-09-24 to 2026-07-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Stretched far below its 200-day average (6+ daily ranges) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.82 mean, 1=Strong Buy…5=Strong Sell) — 30 analysts
- Mean price target$478.01 range $324.00 – $685.00; median $484.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ISRG
- Consensus EPS estimate$2.64 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Competition from other robotic surgery platforms and traditional laparoscopic surgical techniques may limit market adoption and pricing","Dependence on hospital purchasing decisions and capital budgeting cycles creates revenue volatility","Regulatory changes, product recalls, or adverse clinical outcomes could harm reputation and limit market access"]
What changed in the latest 10-Q
AI-assisted comparison of ISRG's 10-Q filed 2026-04-22 against the prior one filed 2025-10-22.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference date updated to March 31, 2026 (newer filing, filed 2026-04-22)
- Reference to 'three months ended March 31, 2026' added (newer filing)
- Reference to Form 10-K for year ended December 31, 2025 added (newer filing, filed 2026-04-22)
- Year references updated to include 2026 in addition to 2025 and 2024 (newer filing)
- Forward-looking statements reference to 'commit' added to list of identifying words (newer filing, filed 2026-04-22)
- Forward-looking statements reference to 'seek' added to list of identifying words (newer filing, filed 2026-04-22)
- Forward-looking statements reference to 'potential' added to list of identifying words (newer filing, filed 2026-04-22)
- Forward-looking statements reference to goals with customers about improving patient outcomes added (newer filing, filed 2026-04-22)
- Specific mention of 'recently completed acquisition of the da Vinci and Ion distribution businesses in Italy, Spain, and Portugal and the transition from a distributor to a direct sales model in those markets' added (newer filing, filed 2026-04-22)
- United States abbreviated as 'U.S.' added in first reference to FDA (newer filing, filed 2026-04-22)
- Removed:
- Reference date of September 30, 2025 removed (older filing, filed 2025-10-22)
- Reference to 'three and nine months ended September 30, 2025, and 2024' removed (older filing)
- Reference to Form 10-K for year ended December 31, 2024 removed (older filing)
- Forward-looking statements reference to 'would' removed from initial list (older filing contained it, newer does not in same position)
- Reworded:
- Geographic conflict description changed from 'the conflict between Ukraine and Russia' to 'the conflict in Ukraine' (newer filing, filed 2026-04-22)
- Conflict description changed from 'conflicts in the Middle East' to 'conflicts in the Middle East, including Israel and Iran' (newer filing, filed 2026-04-22)
- Supply chain disruption description changed from 'difficulties in obtaining' to 'increased difficulties in obtaining' (newer filing, filed 2026-04-22)
- Company founding timeline changed from 'Since our founding 30 years ago' to 'Since our founding over 30 years ago' (newer filing, filed 2026-04-22)
- Reference to regulatory authorities changed from 'Food and Drug Administration' to 'United States ('U.S.') Food and Drug Administration' (newer filing, filed 2026-04-22)
- Acquisition language changed from general 'our completion of and ability to successfully integrate acquisitions' to specific reference including Italy, Spain, Portugal distribution businesses (newer filing, filed 2026-04-22)
- Form 10-K year reference changed from 'December 31, 2024' to 'December 31, 2025' (newer filing, filed 2026-04-22)
- Notes:
- The newer filing's Overview section appears truncated mid-sentence ('Fourth,') so the full scope of changes in that section cannot be assessed
- The older filing's Overview section also appears truncated, preventing full comparison of that subsection
Risk Factors
- Added:
- Newer filing includes 'Gain on sale of business and assets' ($7.9 million) in cash flow statement adjustments (filed 2026-04-22)
- Newer filing shows 'Acquisition of business, net of cash, and intellectual property and other investing activities' ($528.2 million) in investing activities (filed 2026-04-22)
- Newer filing includes 'Repurchase of common stock' ($1,123.2 million) in financing activities for Q1 2026 (filed 2026-04-22)
- Removed:
- Older filing included 'Amortization of contract acquisition assets' ($27.4 million) in nine-month 2025 cash flow statement; not present in newer Q1 2026 statement (filed 2025-10-22)
- Older filing included 'Cash dividends paid by joint venture to noncontrolling interest' ($0 in 2025 nine months); not shown in newer Q1 2026 statement (filed 2025-10-22)
- Older filing included 'Payment of deferred purchase consideration' ($0 in 2025 nine months); not shown in newer Q1 2026 statement (filed 2025-10-22)
- Older filing showed nine-month and full-year comparative periods in income statement; newer filing shows only three-month Q1 2026 vs Q1 2025 (filed 2025-10-22 vs filed 2026-04-22)
- Reworded:
- Cash flow statement line item changed from 'Gain on investments, accretion of discounts, and amortization of premiums on investments, net' in older filing to 'Accretion of discounts, amortization of premiums, and (gains) losses on investments, net' in newer filing
- Cash flow statement line item changed from 'Amortization of intangible assets' in older filing to 'Amortization of intangible and other assets' in newer filing
- Investing activities line item changed from 'Proceeds from sales of investments' and 'Proceeds from maturities of investments' (separately listed in older filing) to combined presentation in newer filing
- Older cash flow statement caption stated 'Nine Months Ended September 30'; newer cash flow caption states 'Three Months Ended March 31'
- Notes:
- The two filings compare different interim periods (nine-month period ending September 30, 2025 vs. three-month period ending March 31, 2026), which limits direct comparability of cash flow line items and operating metrics
- Balance sheet comparison uses different fiscal dates (September 30, 2025 vs. March 31, 2026) and different prior-year comparisons (December 31, 2024 vs. December 31, 2025)
- Financial statement line items and their presentation structure differ between a nine-month filing period and a three-month filing period
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 13 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 6 sells ($201093) — 2 selling insiders
- Last 90 days0 buys · 13 sells ($3M) — 3 selling insiders
- Last 180 days0 buys · 21 sells ($3M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-10. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ISRG's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 20 matched disclosures for ISRG from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding ISRG as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 53,888,510
- Reported value $24,842,063,966
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ISRG had 6,620,078 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ISRG had 1.87% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.39 days to cover at the same settlement.
- Reported short interest (shares) 6,620,078
- Short interest (% of shares outstanding) 1.87%
- Prior settlement (shares) 6,708,471
- Reported change -1.32%
- Days to cover (reported) 1.39
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
- Karl Storz
- Olympus
- Stryker Corporation (SYK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ISRG vs…
Intuitive Surgical is found in…
Frequently asked questions
What does Intuitive Surgical (ISRG) do?
Intuitive Surgical designs, manufactures, and markets robotic-assisted surgical systems for minimally invasive surgery. The company generates revenue from both product sales (surgical systems hardware) and recurring service revenue from maintenance, support, and training. The da Vinci surgical platform is the company's flagship product, used in hospitals and surgical centers worldwide for a wide range of surgical procedures.
What sector is Intuitive Surgical (ISRG) in?
Intuitive Surgical (ISRG) is classified in the Health Care sector. Its industry is medical robotics and surgical equipment. It trades on NASDAQ.
Who are Intuitive Surgical's (ISRG) competitors?
Notable peers of Intuitive Surgical (ISRG) include Medtronic, Johnson & Johnson, Karl Storz, Olympus and Stryker Corporation. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ISRG?
Yes — we hold 20 matched STOCK Act disclosures for ISRG from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Intuitive Surgical (ISRG) overbought or oversold right now?
Intuitive Surgical (ISRG) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ISRG come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.